EMBCV - EMBCV STOCK NEWS

Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced an upcoming conference call to discuss its fiscal second quarter 2023 results on May 12, 2023, at 8:00 a.m. ET. The call will cover financial results, operational updates, and include a Q&A session. Interested parties can access the live webcast through the company's investor relations website or via teleconference. A replay of the call will be available later that day and archived for one year.

With a legacy of nearly 100 years in insulin delivery and a dedicated workforce of approximately 2,000 employees, Embecta aims to empower individuals with diabetes through innovative solutions.

Embecta Corp. (Nasdaq: EMBC) is hosting a symposium at the ATTD 2023 conference on February 24, 2023, emphasizing the crucial role of people with diabetes in their care. Titled “Diabetes Era of Possibilities: Infusing PwD Choice into Practice!”, the session aims to enhance treatment personalization and discuss insulin injection techniques and diabetes technologies for improved outcomes. The symposium will be chaired by Prof. Dr. Lutz Heinemann and feature key speakers from the diabetes healthcare community. The event underscores the importance of collaboration in care plans to improve the quality of life for diabetes patients.

Embecta Corp. (Nasdaq: EMBC) reported its Q1 fiscal year 2023 results, with revenues of $275.7 million, down 4.7% year-over-year. Adjusted net income was $55.4 million, or $0.96 per diluted share. While U.S. revenues fell 1.1%, international revenues decreased 8.7%, though they rose 2.6% in constant currency. The company raised its fiscal year 2023 revenue guidance to $1,084 - $1,107 million, expecting a 4.0% - 2.0% decline reported and -1.5% - 0.5% in constant currency. A quarterly dividend of $0.15 per share was announced. The CEO expressed confidence in achieving strategic priorities and sustainable success.

The Board of Directors of Embecta Corp. (NASDAQ: EMBC) has declared a quarterly cash dividend of $0.15 per share. This dividend, which reflects the company’s commitment to returning value to its shareholders, will be payable on March 13, 2023, to stockholders of record as of February 27, 2023. Embecta is a leading pure-play diabetes care company, leveraging nearly a century of experience in insulin delivery to enhance the lives of people with diabetes. The company's passion is evident through its workforce of more than 2,000 employees worldwide, focusing on innovative solutions and partnerships.

Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced its participation in several upcoming investor conferences. Management will hold virtual meetings on February 15, 2023, for the 2023 BTIG Medical Technology Conference. A presentation is scheduled for March 6, 2023, at 2:00 p.m. ET during the 2023 JP Morgan Global High Yield and Leveraged Finance Conference in Miami, FL. Additionally, a virtual session will occur on March 14, 2023, at 8:00 a.m. ET for the 2023 Oppenheimer 33rd Annual Healthcare Conference. Audio webcasts of these events will be available on Embecta’s investor relations website.